1. |
Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update [J]. Hepatology, 2011, 53(3):1020-1022.
|
2. |
Nemeth E, Baird AW, O’farrelly C. Microanatomy of the liver immune system [J]. Semin Immunopathol, 2009, 31(3): 333-343.
|
3. |
孔丽, 姚树坤, 刘金星, 等. 原发性肝癌患者细胞免疫功能变化及其与转归的关系 [J].中华肝脏病杂志, 2005, 13(3): 194-197.
|
4. |
沈顺利, 梁力建. 调节性T 细胞与原发性肝癌的免疫治疗 [J]. 中华肝胆外科杂志, 2010, 16(4):314-317..
|
5. |
Cany J, Tran L, Gauttier V, et al. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion? [J]. Immunotherapy, 2011, 3(4 Suppl): 32-34.
|
6. |
Shen X, Li N, Li H, et al. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma [J]. J Cancer Res Clin Oncol,2010, 136(11): 1745-1754.
|
7. |
张妍, 迟晓燕, 崔保霞. CD4+CD25+ 调节性T 细胞与肿瘤免疫研究进展 [J].生命科学, 2010, 22(4):362-366..
|
8. |
Mcnally A, Hill GR, Sparwasser T, et al. CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis [J]. Proc Natl Acad Sci USA, 2011, 108(18):7529-7534.
|
9. |
Chen Z, Yan JJ, Ni JL, et al. Correlation between the distribution of CD4+CD25+ regulartory T (Treg) cells and T-cell infiltration in microenvironment of hepatocellular carcinoma [J]. Bulletin of Chinese Cancer, 2007, 16(6): 461-463.
|
10. |
杨曌, 牛微, 尚小云, 等. 肝癌患者CD4+CD25+ 调节性T 细胞的检测及其临床意义 [J]. 中国癌症杂志, 2007, 87(1):62-64.
|
11. |
张关亭. 消化道肿瘤患者外周血中CD4+CD25+ 调节性T 细胞检测的临床意义 [J]. 现代预防医学, 2011, 38(2):330-331, 337.
|
12. |
张晟晃, 谭小宇, 陈念平. 肝癌患者外周血T 淋巴细胞亚群的测定及临床意义 [J]. 中国医院用药评价与分析, 2010, 10(2):159-160..
|
13. |
陈理明, 王少彬, 陈俊辉. 射频消融治疗恶性肿瘤后T 淋巴细胞亚群的改变 [J].医学综述, 2006, 12(23):1452-1454..
|
14. |
全毅, 刘建刚, 蔡悦成, 等. 经肝动脉化疗栓塞联合肿瘤间质治疗肝癌后免疫功能改变 [J]. 南方医科大学学报, 2009,29(11): 2288-2290.
|
15. |
罗小玲. 原发性肝癌患者手术前后外周血T 淋巴细胞亚群变化分析 [J]. 广西医学 , 2000, 22(3): 437-438.
|
16. |
杨永久, 陈大志, 金中奎, 等. 原发性肝癌肝移植患者围手术期免疫功能的变化及其临床意义 [J]. 中国普通外科杂志,2009, 18(1):86-89..
|
17. |
汤钊猷. 21 世纪初肝脏外科展望 [J]. 中华肝胆外科杂志,2005, 11(2): 73-74.
|
18. |
Zhang XF, Meng B, Qi X, et al. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: The surgeon’s role in survival [J]. Eur J Surg Oncol,2009, 35(6): 622-628.
|
19. |
廖维甲, 梅铭惠. 预测肝细胞癌术后复发转移的研究进展 [J].实用医学杂志, 2009, 25(24):4101-4102..
|
20. |
Khazaie K, von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer [J]. Semin Cancer Biol, 2006, 16(2): 124-136.
|
21. |
Mendes R, Bromelow KV, Westby M, et al. Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood [J]. Cytometry, 2000,39(1): 72-78.
|
22. |
曹驰, 李彩霞. 原发性肝癌的免疫状态与预后的相关性分析[J]. 肿瘤防治杂志, 2004, 11(2):127-130..
|
23. |
Liu Y, Poon RT, Hughes J, et al. Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma [J]. Clin Immunol, 2005, 114(2): 174-182.
|
24. |
陈中, 晏建军, 倪家连, 等. 肝细胞癌微环境中CD4+CD25+ 调节性T 细胞的分布及其临床病理意义 [J]. 中华肝胆外科杂志,2007, 13(10):678-681..
|
25. |
樊永丽, 任秀宝. 调节性T 细胞与肝细胞肝癌免疫的研究进展 [J]. 国际免疫学杂志, 2011, 34(2):127-130..
|
26. |
Wang Y, Ma Y, Fang Y, et al. Regulatory T cell: A protection for tumor cells[ J]. J Cell Mol Med, 2011, 34(2): 127-130.
|
27. |
高建, 陈敏, 彭明利, 等. 肝癌细胞裂解物致敏的树突状细胞疫苗体外诱导特异性抗肝癌免疫 [J]. 中华肝脏病杂志, 2005,13(3):198-201..
|
28. |
Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma [J]. Hepatology,2009, 49(1): 124–132.
|
29. |
Yang X, Zhu H, Hu Z. Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth [J]. Vaccine, 2010, 28(43):7130-7135.
|
30. |
罗颖蓝. 树突状细胞疫苗在肝癌免疫治疗中的研究进展 [J].国际检验医学杂志, 2010, 31(9):971-973..
|
31. |
Teitz-Tennenbaum S, Li Q, Davis MA, et al. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer [J]. J Immunother,2009, 32(6): 602-612.
|
32. |
Zheng N, Ye SL, Sun RX, et al. Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma [J]. World J Gastroenterol,2002, 8(2): 233-236.
|
33. |
Hao MZ, Lin HL, Chen Q, et al. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study [J].Chin J Cancer, 2010, 29(2): 172-177.
|
34. |
张效东, 周宁新, 徐迎新. DC-CIK 过继转移联合微创技术治疗消化道肿瘤 [J]. 北京师范大学学报:自然科学, 2010,46(4):489-491..
|
35. |
余文昌, 叶韵彬, 周东, 等. 肝癌术后补充动脉插管化疗栓塞术联合细胞免疫治疗对复发率及生存率的影响 [J]. 微创医学, 2009, 4(5):459-461..
|
36. |
Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial [J]. J Immunother, 2005, 28(5): 496-504.
|
37. |
王福立, 李岩, 梁婧,等. TACE 术联合自体CIK 细胞治疗原发性肝癌 [J]. 医学与哲学( 临床决策论坛版), 2011, 32(4):27-28, 33..
|
38. |
Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma [J].Dig Liver Dis, 2009, 41(1): 36-41.
|
39. |
Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma [J]. J Hepatol, 2011, 54(4): 830-834.
|